Marie-helene Lafeuille

1190 Avenue Des Canadiens De Montréal
Montreal, QC H3B4W5, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 120 publications

Real-world treatment and healthcare resource utilization patterns among patients with advanced non-small cell lung cancer treated with amivantamab: a retrospective study using insurance claims data.

Real-world treatment and healthcare resource utilization patterns among patients with advanced non-small cell lung cancer treated with amivantamab: a retrospective study using insurance claims data.

Journal: BMC pulmonary medicine
Published: February 12, 2026

Real-World Comparison of Overall Survival Among Patients With and Without Inherited Retinal Diseases.

Real-World Comparison of Overall Survival Among Patients With and Without Inherited Retinal Diseases.

Journal: Vision (Basel, Switzerland)
Published: January 08, 2026

Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma.

Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma.

Journal: Future science OA
Published: July 12, 2025

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.

A comparison of healthcare resource utilization and costs between patients with chronic lymphocytic leukemia treated with first-line ibrutinib or acalabrutinib using two large US real-world databases.

Journal: Journal of comparative effectiveness research
Published: April 22, 2025

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Journal: Leukemia & lymphoma
Published: October 01, 2024

Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non-small cell lung cancer.

Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non-small cell lung cancer.

Journal: Journal of managed care & specialty pharmacy
Published: September 11, 2024

Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.

Comparison of Time to Next Treatment or Death Between Front-Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant-Ineligible Patients With Multiple Myeloma.

Journal: Cancer medicine
Published: August 07, 2024

Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective.

Predictors of High Healthcare Cost Among Patients with Generalized Myasthenia Gravis: A Combined Machine Learning and Regression Approach from a US Payer Perspective.

Journal: Applied health economics and health policy
Published: June 11, 2024

Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapy.

Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapy.

Journal: Pharmacology research & perspectives
Published: June 07, 2024

Non-Medical Switching or Discontinuation Patterns among Patients with Non-Valvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States: A Claims-Based Analysis.

Non-Medical Switching or Discontinuation Patterns among Patients with Non-Valvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States: A Claims-Based Analysis.

Journal: Journal of market access & health policy
Published: May 07, 2024

Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation.

Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation.

Journal: Blood neoplasia
Published: April 08, 2024

Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.

Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.

Journal: Journal of medical economics
Published: February 23, 2024
Showing 1-12 of 120

Last Updated: 09/26/2026